logo-loader

Aimmune Therapeutics says peanut allergy drug trial met primary endpoint, plans to file for FDA approval by year-end

Last updated: 09:28 20 Feb 2018 EST, First published: 04:28 20 Feb 2018 EST

Peanuts
The Nasdaq-listed company said it plans to file for US FDA approval by the end of the year

Aimmune Therapeutics Inc. shares jumped over 10% in pre-market trading on Tuesday after the company said a late-stage trial for its AR101 peanut allergy drug met its primary endpoint.

The Nasdaq-listed company said it plans to file for Food and Drug Administration approval by the end of the year, and expects a filing in Europe in the first half of 2019.

Results of Phase III study

It said of the 496 patients aged 4 to 17 years old who received treatment in the Phase III study, 67% of patients who took AR101 tolerated at least 600 mg of peanut protein with no more than mild symptoms, compared to 4% of placebo patients.

The firm also added that about 50% of AR101 trial patients tolerated 1,000 mg of peanut protein, compared with 2% of placebo patients.

In pre-market New York trading, Aimmune shares were up 10.9% at US$37.20.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

10 minutes ago